Effect of Diltiazem, a Moderate CYP3A Inhibitor, on the Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein Inhibitor, in Healthy Subjects

The Conduct of In Vitro and In Vivo Drug‐Drug Interaction Studies: A PhRMA Perspective

Thorir D. Bjornsson, John T. Callaghan, Heidi J. Einolf et al. · The Journal of Clinical Pharmacology · 2003 · 309 citations

Medicine, Pharmacokinetics, Pharmacology +17

Torcetrapib‐induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

M J Forrest, Daniel M. Bloomfield, Richard J. Briscoe et al. · British Journal of Pharmacology · 2008 · 288 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

Rajesh Krishna, Matt S. Anderson, Arthur Bergman et al. · The Lancet · 2007 · 277 citations

Life Sciences, Pharmacology, Pharmacotherapy +15

Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole

Shirley M. Tsunoda, R VELEZ, L VONMOLTKE et al. · Clinical Pharmacology & Therapeutics · 1999 · 258 citations

Medicine, Pharmacokinetics, Pharmacology +17

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

Daniel M. Bloomfield, Gary L. Carlson, Aditi Sapre et al. · American Heart Journal · 2008 · 244 citations

Pharmacy, Pharmacokinetics, Pharmacology +12